Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update

Rhea-AI Summary

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) reported Q2 FY26 results and a corporate update for the quarter ended 31 December 2025. Key highlights: strengthened Phase 2 ATH434 data in Multiple System Atrophy (MSA), Fast Track designation from the FDA, ongoing Phase 3 planning and an expected FDA End‑of‑Phase‑2 meeting in mid‑2026. Cash and equivalents were A$49.2 million with operating cash outflows of A$5.28 million for the quarter.

The company continues scientific presentations, advisory engagement and partnering discussions while bolstering board and executive leadership to support late‑stage development.

Positive

• Phase 2 efficacy strengthened: 75 mg group effect improved from -2.4 to -2.8 (treatment effect 35% vs placebo)
• FDA Fast Track designation granted for ATH434, enabling more frequent regulatory interactions
• Cash balance of A$49.2M at 31 December 2025 with A$5.28M operating outflow for the quarter

Negative

• Phase 3 funding not yet secured; company is exploring partnering and non‑dilutive options
• Phase 3 timing remains contingent on FDA feedback from a planned mid‑2026 EOP2 meeting

News Market Reaction

-2.76%

3 alerts

-2.76% News Effect

-$2M Valuation Impact

$59M Market Cap

0.1x Rel. Volume

On the day this news was published, ATHE declined 2.76%, reflecting a moderate negative market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $59M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Cash balance: A$49.2 million Operating cash outflows: A$5.28 million Related party payments: A$705k +5 more

8 metrics

Cash balance A$49.2 million Cash and cash equivalents as of 31 December 2025 (Q2 FY26)

Operating cash outflows A$5.28 million Operating cash outflows for the Q2 FY26 quarter

Related party payments A$705k Quarterly payments to related parties under ASX Listing Rule 4.7C

Commercial opportunity US$2.4 billion Estimated peak commercial opportunity for ATH434 in MSA cited in the update

UMSARS change -2.8 points Modified UMSARS Part I1 change at 52 weeks, 75 mg dose vs baseline

Relative treatment effect 35% Improved relative treatment effect vs placebo after covariate adjustment

Dose level 75 mg ATH434 dose group showing strengthened efficacy signal at 52 weeks

Study duration 52 weeks Follow-up period for efficacy and symptom assessments in Phase 2 trial

Market Reality Check

Price: $3.02 Vol: Volume 11,717 vs 20-day a...

normal vol

$3.02 Last Close

Volume Volume 11,717 vs 20-day average 14,139 (relative volume 0.83x) indicates subdued trading ahead of this update. normal

Technical Shares at $3.26 are trading below the $4.15 200-day moving average and sit 53.43% under the 52-week high of $7.00.

Peers on Argus

ATHE fell 3.55% while several biotech peers also traded lower (e.g., OSTX -3.5%,...

ATHE fell 3.55% while several biotech peers also traded lower (e.g., OSTX -3.5%, UNCY -2.91%, CVM -6.23%), but mixed moves in ACET (+0.59%) and OVID (flat) and no momentum scanner hits suggest a stock-specific move rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Shareholder letter	Positive	-1.5%	Detailed 2025 progress, strong Phase 2 data and 2026 objectives for ATH434.
Nov 12	Conference appearance	Neutral	+3.3%	CEO corporate update presentation at Bell Potter Healthcare Virtual Conference.
Nov 10	Clinical data update	Positive	+8.3%	New ATH434 Phase 2 analyses on orthostatic hypotension and disease progression.
Oct 31	Quarterly cash report	Positive	-8.5%	Q1 FY26 Appendix 4C with strong cash, raise proceeds and reinforced efficacy signal.
Oct 09	Clinical data presentation	Positive	+4.4%	Positive Phase 2 ATH434-201 data presented at MDS Congress, including strong efficacy.

Pattern Detected

Recent ATH434 and corporate updates have produced mixed reactions: some positive clinical news aligned with price gains, while other seemingly favorable updates coincided with selloffs, indicating inconsistent sensitivity to news.

Recent Company History

Over the past few months, Alterity has consistently highlighted Phase 2 ATH434 data in MSA and its path toward a pivotal Phase 3 program. Prior updates emphasized strengthened efficacy signals on modified UMSARS, regulatory planning for an End-of-Phase 2 FDA meeting in mid-2026, and a large estimated $2.4B market opportunity. Quarterly Appendix 4C releases showed a solid cash position alongside ongoing development spending. Today’s Q2 FY26 cash flow and corporate update continues this narrative of advancing ATH434 toward Phase 3 with a focus on balance sheet strength and partnering.

Market Pulse Summary

This announcement highlights strengthened Phase 2 ATH434 data in MSA, ongoing FDA engagement toward ...

Analysis

This announcement highlights strengthened Phase 2 ATH434 data in MSA, ongoing FDA engagement toward an End‑of‑Phase 2 meeting in mid-2026, and a cash position of A$49.2 million after Q2 FY26 operating outflows of A$5.28 million. It reinforces a large cited commercial opportunity of US$2.4 billion and active Phase 3 planning and partnering efforts. Investors may watch for future milestones such as finalized Phase 3 design, formal regulatory feedback, and any partnering transactions.

Key Terms

multiple system atrophy, fast track designation, end-of-phase-2, orthostatic hypotension, +4 more

8 terms

multiple system atrophy medical

"ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses"

A progressive neurological disorder that damages multiple areas of the nervous system, causing problems with movement, balance and involuntary functions like blood pressure and bladder control; think of it as critical wiring in the body slowly failing. Investors care because the condition defines the size and urgency of the market for treatments, influences clinical trial difficulty and regulatory risk, and can lead to high per-patient pricing but also greater development uncertainty.

fast track designation regulatory

"ATH434 has been granted Fast Track designation by the FDA"

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

end-of-phase-2 regulatory

"preparation for FDA End-Of-Phase-2 meeting in mid-2026"

A planned review that marks the completion of a mid-stage clinical trial program and checks whether the results and development plan are strong enough to move into large-scale testing. For investors, it is a key milestone because a positive outcome or clearance to proceed reduces the risk, signals progress toward potential approval and market launch, and often influences company value much like passing a safety inspection before a big public rollout.

orthostatic hypotension medical

"Differences in baseline severity of orthostatic hypotension largely explained the differing responses"

A sudden drop in blood pressure that happens when a person stands up from sitting or lying down, causing dizziness, lightheadedness, or fainting. For investors, it matters because treatments, drug side effects, or medical-device performance tied to this condition can affect regulatory approval, product labeling, and patient adoption—similar to a car that stalls on a hill, creating safety concerns that influence market value and sales prospects.

clinical advisory board technical

"Alterity held a Clinical Advisory Board meeting in December 2025"

A clinical advisory board is a group of independent medical and scientific experts a company consults to guide clinical development, trial design, regulatory strategy and product use. Like a navigation team advising a ship’s captain, they bring real‑world experience and credibility that can speed development, reduce regulatory and clinical risk, and influence investor confidence by signaling that the science and path to market are being thoughtfully managed.

chemistry, manufacturing and controls (cmc) technical

"regulatory interactions across clinical pharmacology and non-clinical topics and chemistry, manufacturing and controls (CMC)"

Chemistry, manufacturing and controls (CMC) is the set of scientific and operational steps that show how a drug or biologic is made, what goes into it, and how its quality is consistently checked—think of it as the recipe, the factory process, and the quality checklist for a medicine. Investors care because strong CMC reduces risks around regulatory approval, production delays, batch failures and unexpected costs, directly affecting a product’s ability to reach market and generate revenue.

randomized, double-blind medical

"ATH434-201 randomized, double-blind Phase 2 trial in MSA"

A randomized, double-blind study is a clinical trial design where participants are assigned by chance to different groups (for example, a new treatment or a control) and neither the participants nor the researchers know who is in which group. This setup reduces conscious or unconscious bias—think of it like a blind taste test—so results are more reliable and investors can have greater confidence that reported effects reflect the treatment itself rather than expectations or selective reporting.

alpha-synuclein medical

"“Relationship Between Alpha-Synuclein Aggregation Profiles, Imaging Biomarkers, and Disease Severity"

A small brain protein that helps nerve cells function, which can misfold and clump together in certain neurodegenerative diseases. Investors care because these clumps are both a target for new therapies and a potential marker used in clinical trials and diagnostics; success or failure of drugs aimed at alpha-synuclein can strongly affect a developer’s clinical prospects, regulatory chances, and market value. Think of it as a faulty part in a machine that companies try to repair or remove.

AI-generated analysis. Not financial advice.

− Phase 2 Data Strengthened, Strong Cash Position, and Phase 3 Planning Well Advanced −

Highlights

• Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter.
• Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026.
• Ongoing partnering and strategic discussions with pharmaceutical companies and corporate advisers to explore non-dilutive pathways to fund Phase 3 development.
• Board and executive leadership strengthened to support Alterity through its next stage of clinical development, partnering and commercial planning.
• Cash balance of A$49.2 million at 31 December 2025.
  
  

MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today released its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 December 2025 (Q2 FY26).

David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics, commented, “We continued to advance our Multiple System Atrophy (MSA) program on multiple fronts, including new analyses of the Phase 2 data that increase our overall confidence in ATH434’s potential as a disease-modifying therapy for this devastating disease. We also made significant strides in planning for a series of meetings with the U.S. FDA, culminating in a planned End-of-Phase 2 (EOP2) meeting in mid-2026.”

Dr. Stamler continued, “During the quarter, we delivered several scientific presentations highlighting the Phase 2 data that support the potential commercial opportunity of US$2.4 billion for ATH434 in MSA. The growing body of data strengthen our conviction in ATH434 as a first-in-class disease-modifying therapy for MSA.”

ATH434 Clinical and Regulatory Update

Phase 2 Clinical Program & Regulatory Progress
Alterity continued to build on the positive results from the ATH434-201 randomized, double-blind Phase 2 trial in MSA, while progressing regulatory planning activities to support advancement into late-stage development. During the quarter, the Company advanced its engagement strategy with the U.S. Food and Drug Administration (FDA), including preparation for regulatory interactions across clinical pharmacology and non-clinical topics and chemistry, manufacturing and controls (CMC).

These activities are focused on preparation for a planned End-of-Phase-2 meeting with the FDA, targeted for mid-2026. The primary objective of this meeting is to align with the agency on the design and requirements of a pivotal Phase 3 clinical trial in MSA, including key elements such as endpoints, patient population and the overall development pathway. The Company remains confident in its ongoing engagement with the FDA and the clarity of the regulatory path toward Phase 3 development.

In addition, Alterity also presented additional analyses from the ATH434-201 randomised, double-blind Phase 2 trial in MSA. A new analysis of modified UMSARS Part I¹ data was presented at the International Congress of Parkinson’s Disease and Movement Disorders, incorporating baseline orthostatic² blood pressure change as a covariate. In this analysis, the efficacy signal in the 75 mg dose group at 52 weeks strengthened from -2.4 to -2.8 points, improving the relative treatment effect from 30% to 35% versus placebo. Differences in baseline severity of orthostatic hypotension largely explained the differing responses observed between the 50 mg and 75 mg dose groups. ATH434 also demonstrated a beneficial effect on orthostatic hypotension symptoms, with placebo-treated participants worsening over 52 weeks while participants in both active treatment groups remained stable.

ATH434 has been granted Fast Track designation by the FDA, reflecting the seriousness of MSA, the significant unmet medical need and the potential of ATH434 to address this need. This designation enables more frequent regulatory interactions and supports an efficient review process as Alterity advances ATH434 toward a pivotal Phase 3 program.

Phase 3 Development Planning and Timeline
Alterity also continued planning activities during the quarter to support the progression of ATH434 into a pivotal Phase 3 clinical program in MSA. The Company is focused on progressing the key elements required to initiate late-stage development, including clinical trial design, regulatory engagement, manufacturing and supply planning, and operational readiness.

The timing and execution of Phase 3 will continue to be informed by regulatory guidance and operational considerations. Alterity’s strong balance sheet and active engagement with potential partners provide flexibility in determining the optimal pathway to advance ATH434 development.

Scientific and Clinical Engagement
During the quarter, Alterity actively engaged with the global neurology community through multiple scientific presentations at leading international congresses. These presentations formed an important component of the Company’s strategy to disseminate clinical data, engage with key opinion leaders and specialists, and further test and refine the interpretation of Phase 2 results for ATH434 in MSA. The medical and scientific meetings provide an opportunity for peer discussion of clinical, biomarker and imaging data from the ATH434-201 trial, contributing to a deeper understanding of treatment response, patient selection and disease characteristics.

In addition, Alterity held a Clinical Advisory Board meeting in December 2025 comprising key opinion leaders in movement disorders and autonomic disorders. The meeting focused on a detailed review of data from the ATH434-201 Phase 2 study and provided expert input into the design and planning of the proposed Phase 3 clinical program. Insights from these scientific dialogues will further inform Phase 3 trial design considerations, including patient selection, endpoints and operational execution.

During the quarter, Alterity delivered the following presentations on the ATH434-201 Phase 2 trial:

• October 2025 – International Congress of Parkinson’s Disease and Movement Disorders (MDS), Title of Oral Platform Presentation: “ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy”
• October 2025 – MDS, Title: “Relationship Between Alpha-Synuclein Aggregation Profiles, Imaging Biomarkers, and Disease Severity in a Phase 2 Study of ATH434 in MSA”
• October 2025 – MDS, Title: “Differences Between Clinical and Imaging Phenotypes in Phase 2 Study of ATH434 in Multiple System Atrophy”
• November 2025 – International Symposium on the Autonomic Nervous System, Title: “Efficacy of ATH434 in Multiple System Atrophy (MSA) is Affected by Baseline Disease Characteristics”
  
  

Partnering and Strategic Discussions

In parallel with advancing the ATH434 development program, Alterity broadened partnering discussions with a number of pharmaceutical companies. These discussions reflect growing industry interest in ATH434’s differentiated clinical profile, orphan disease status, and validated commercial potential.

The Company is evaluating a range of strategic pathways to support the advancement of ATH434, including potential partnership structures, and is also in the process of engaging with external advisers to assist in assessing these options. These activities are occurring alongside ongoing regulatory and Phase 3 planning and are intended to preserve flexibility and maximising long-term shareholder value as the Company progresses toward Phase 3 development.

Corporate and Financial Update

Governance and Leadership
During the quarter, Alterity strengthened its governance and leadership structure to support the Company’s transition into late-stage development and active partnering discussions.

At the Company’s Annual General Meeting held in November 2025, Geoffrey Kempler retired as Non-Executive Chair and Director, Brian Meltzer retired as Non-Executive Director, and Julian Babarczy was appointed Chair of the Board. Mr Babarczy is an experienced company director and investor with over 20 years’ experience across Australia’s corporate and funds management sectors. He brings a strong track record in guiding emerging growth companies through periods of strategic transition, capital management and value realisation.

In addition, Chief Executive Officer Dr David Stamler was appointed to the Board as Managing Director, further strengthening alignment between the Board and executive leadership. Dr Stamler brings deep clinical development and regulatory experience in neurology, including involvement in three FDA approvals in neurology, and continues to lead Alterity’s clinical, regulatory and strategic execution.

The Company also expanded its leadership with the appointment of a Head of Investor Relations and Communications, a Head of Corporate Strategy and Operations, and a Head of Regulatory Affairs and Quality Assurance, reflecting an increased focus on institutional engagement, strategic partnering and operational execution.

Together, these governance and leadership enhancements position Alterity strongly to execute its next phase of growth, including Phase 3 development planning, regulatory engagement and the pursuit of value-accretive partnering opportunities.

Cash Position
As of 31 December 2025, Alterity held cash and cash equivalents of A$49.2 million. Operating cash outflows for the quarter were A$5.28 million. The Company believes its strong cash position provides a solid runway to progress regulatory, clinical and commercial objectives while advancing partnering discussions from a position of financial strength.

In accordance with ASX Listing Rule 4.7C, payments of A$705k made to related parties and their associates during the quarter included non-executive directors’ fees, managing director salary and bonus payments, consulting fees, remuneration and superannuation at commercial rates.

Outlook

Alterity enters the second half of FY26 with strong momentum, underpinned by:

• Robust and strengthened Phase 2 clinical data;
• A compelling, independently validated commercial opportunity for ATH434 in MSA;
• A strong balance sheet; and
• Meaningful engagement with potential strategic partners.
  
  

The Company remains focused on advancing ATH434 toward a pivotal Phase 3 program, progressing regulatory alignment with the FDA, and pursuing partnering opportunities that maximise long-term value for shareholders while minimising dilution.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is initially focused on developing disease modifying therapies in Parkinson’s disease and related disorders. Alterity has demonstrated clinically meaningful efficacy for its lead asset, ATH434, in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with Multiple System Atrophy (MSA), a rare and rapidly progressive Parkinsonian disorder. ATH434 recently reported positive data in its open label Phase 2 clinical trial in advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at www.alteritytherapeutics.com.

References:

¹ Unified MSA Rating Scale, Part I (historical review) assess activities of daily living. Domains assessed include speech, swallowing, handwriting, cutting food/handling utensils, dressing, hygiene, walking, falling, orthostatic symptoms, urinary function, sexual function and bowel function.
² Orthostatic hypotension is a form of low blood pressure that might cause dizziness, lightheadedness or fainting when rising from sitting or lying down. Source: Mayo Clinic.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors
Tara Speranza
Head of Investor Relations and Communications
tsperanza@alteritytx.com

Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386

Media
Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520

Forward Looking Statements

This press release contains "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are described in the sections titled “Risk Factors” in the Company’s filings with the SEC, including its most recent Annual Report on Form 20-F as well as reports on Form 6-K, including, but not limited to the following: statements relating to the Company's drug development program, including, but not limited to the initiation, progress and outcomes of clinical trials of the Company's drug development program, including, but not limited to, ATH434, and any other statements that are not historical facts. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to the difficulties or delays in financing, development, testing, regulatory approval, production and marketing of the Company’s drug components, including, but not limited to, ATH434, the ability of the Company to procure additional future sources of financing, unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug compounds, including, but not limited to, ATH434, that could slow or prevent products coming to market, the uncertainty of obtaining patent protection for the Company's intellectual property or trade secrets, the uncertainty of successfully enforcing the Company’s patent rights and the uncertainty of the Company freedom to operate.

Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

FAQ

What did Alterity (ATHE) report for cash and operating cash outflow in Q2 FY26?

According to Alterity, the company held A$49.2 million cash and equivalents at 31 December 2025. Operating cash outflows were A$5.28 million for the quarter, which the company says supports near‑term regulatory and Phase 3 planning activities.

How did the ATH434 Phase 2 results change in Alterity's Q2 FY26 update?

According to Alterity, a new analysis strengthened the 75 mg group's 52‑week effect from -2.4 to -2.8 points. This raised the relative treatment effect versus placebo to about 35%, and identified baseline orthostatic hypotension as an influencing factor.

What is the regulatory next step and timeline for ATH434 mentioned by Alterity (ATHE)?

According to Alterity, the company is preparing for an FDA End‑of‑Phase‑2 meeting targeted for mid‑2026. The meeting aims to align on pivotal Phase 3 design, endpoints, patient population, and CMC topics to support late‑stage development.

Does Alterity have FDA designation for ATH434 and what does it mean for ATHE shareholders?

According to Alterity, ATH434 received Fast Track designation from the FDA, which can enable more frequent agency interactions and a potentially more efficient review. This may accelerate regulatory dialogue ahead of pivotal Phase 3 planning.

What partnering activity did Alterity describe for ATH434 in the Q2 FY26 update?

According to Alterity, the company is in active discussions with multiple pharmaceutical companies and advisers to assess partnership structures. These talks aim to identify non‑dilutive or strategic funding pathways to support Phase 3 development.

How did Alterity change its governance and leadership during the quarter ending 31 December 2025?

According to Alterity, the company appointed Julian Babarczy as Chair and added the CEO, Dr David Stamler, to the Board as Managing Director. Additional hires included heads of investor relations, corporate strategy and regulatory affairs.